Safety enhancement of a genetically modified live rabies vaccine strain by introducing an attenuating Leu residue at position 333 in the glycoprotein

• Published in: Vaccine Vol. 39; no. 28; pp. 3777 - 3784
• Main Authors: Ito, Naoto, Okamoto, Takuya, Sasaki, Michihito, Miyamoto, Shoya, Takahashi, Tatsuki, Izumi, Fumiki, Inukai, Maho, Jarusombuti, Supasiri, Okada, Kazuma, Nakagawa, Kento, Fujii, Yuji, Nishiyama, Shoko, Masatani, Tatsunori, Sawa, Hirofumi, Sugiyama, Makoto
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Ltd 23.06.2021; Elsevier Limited
• Subjects: Animals; Antibodies; Antibody response; Attenuated live vaccine; Attenuation; Developing countries; Genetic modification; Genetics; Genomes; Genotype & phenotype; Glycoprotein; Glycoproteins; Inoculation; LDCs; Lethality; Leucine; Mutation; Nucleotides; Rabies; Residues; Reverse genetics; Reversion; Safety; Suckling behavior; Vaccines; Virulence; Viruses; Japan; Leucine; Rabies; Reverse genetics; Glycoprotein; Attenuated live vaccine
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2021.05.002

•A live rabies vaccine candidate, ERA-G333Leu, having Leu at G333 was established.•ERA-G333Leu is highly and stably attenuated.•ERA-G333Leu induces neutralizing antibody response and protected immunity. To improve the safety of genetically modified live rabies vaccine strains, most studies have utilized an attenuating Arg-to-Glu mutation at position 333 in the glycoprotein (G333), which is responsible for attenuation of the live vaccine strain SAG2. The Glu residue requires two nucleotide substitutions to revert to pathogenic Arg, thus significantly lowering the probability of pathogenic reversion caused by the Glu-to-Arg mutation at G333. However, only one nucleotide substitution is sufficient to convert the Glu residue to another pathogenic residue, Lys, and thereby to cause pathogenic reversion. This indicates a potential safety problem of SAG2 and the live vaccine candidates attenuated by Glu at G333. In this study, aiming to solve this problem, we examined the utility of a Leu residue, which requires two nucleotide substitutions to be both Arg and Lys, as an attenuating mutation at G333. Using a reverse genetics system of the live vaccine strain ERA, we generated ERA-G333Leu by introducing an Arg-to-Leu mutation at G333. Similar to ERA-G333Glu, which is attenuated by an Arg-to-Glu mutation at G333, ERA-G333Leu did not cause obvious clinical signs in 6-week-old mice after intracerebral inoculation. Importantly, after 10 passages in suckling mouse brains, ERA-G333Glu acquired a pathogenic Lys or Arg at G333 and a high level of lethality in mice, whereas ERA-G333Leu retained the attenuating Leu at G333 and only showed a modest level of virulence probably caused by a mutation at G194. In addition, ERA-G333Leu and ERA-G333Glu induced neutralizing antibody response and protective immunity in mice with similar efficiencies. The results demonstrate that, compared to ERA-G333Glu, ERA-G333Leu is more stably attenuated, also indicating the high utility of a Leu residue as an attenuating mutation at G333 in the development of live rabies vaccine strains with a high level of safety.